Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 4/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥15.06 |
52 Week High | CN¥19.50 |
52 Week Low | CN¥11.32 |
Beta | 0.71 |
11 Month Change | -10.57% |
3 Month Change | 15.85% |
1 Year Change | -19.89% |
33 Year Change | -57.64% |
5 Year Change | -35.36% |
Change since IPO | -37.25% |
Recent News & Updates
Recent updates
Shareholder Returns
2196 | HK Pharmaceuticals | HK Market | |
---|---|---|---|
7D | 1.5% | -7.2% | -0.6% |
1Y | -19.9% | -5.9% | 14.2% |
Return vs Industry: 2196 underperformed the Hong Kong Pharmaceuticals industry which returned -2.9% over the past year.
Return vs Market: 2196 underperformed the Hong Kong Market which returned 15% over the past year.
Price Volatility
2196 volatility | |
---|---|
2196 Average Weekly Movement | 8.8% |
Pharmaceuticals Industry Average Movement | 6.8% |
Market Average Movement | 8.9% |
10% most volatile stocks in HK Market | 18.9% |
10% least volatile stocks in HK Market | 4.2% |
Stable Share Price: 2196 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2196's weekly volatility (9%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1994 | 39,309 | Deyong Wen | www.fosunpharma.com |
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. The company’s product pipeline includes HLX15, a recombinant anti-CD38 human monoclonal antibody injection for treatment of multiple myeloma; HLX13, an anti-CTLA-4 human monoclonal antibody for the treatment of melanoma, renal cell carcinoma, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, malignant pleural mesothelioma, and esophageal squamous cell cancer; SZEY-2108 for the treatment of carbapenem resistant enterobacteriaceae (CRE) infection; XH-S003 for the treatment of IgA nephropathy and other glomerular diseases; HLX43, an antibody-drug for the treatment of metastatic solid tumors; XS-03 for the treatment of RAS-mutated advanced solid tumor; OP0595, a nacubactam for the treatment of aerobic gram-negative bacteria; XH-S002 for the treatment of ischemic stroke and transient ischemic attack which are in Phase I; HLX26, anti-LAG-3 humanized monoclonal antibody injection for the treatment of metastatic colorectal cancer; FCN-338 for the treatment of myeloid malignancies; FCN-159 for the treatment of langerhans cell histiocytosis; HLX208, a BRAF V600E inhibitor for the treatment of non-small cell lung cancer which are in phase II; FS-1502, a HER2 humanized monoclonal antibody-monomethyl auristatin F injection for the treatment of HER2-positive locally advanced or metastatic breast cancer; FCN-159 for the treatment of neurofibromatosis; ET-26, a methoxyetomidate hydrochloride for the treatment of general anesthesia which are in phase III.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Fundamentals Summary
2196 fundamental statistics | |
---|---|
Market cap | HK$70.46b |
Earnings (TTM) | HK$2.32b |
Revenue (TTM) | HK$45.61b |
33.8x
P/E Ratio1.7x
P/S RatioIs 2196 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
2196 income statement (TTM) | |
---|---|
Revenue | CN¥41.61b |
Cost of Revenue | CN¥21.83b |
Gross Profit | CN¥19.78b |
Other Expenses | CN¥17.67b |
Earnings | CN¥2.11b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.79 |
Gross Margin | 47.55% |
Net Profit Margin | 5.08% |
Debt/Equity Ratio | 55.0% |
How did 2196 perform over the long term?
See historical performance and comparison